Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma

Head and Neck

Volumn 35, Issue 9, 2013, Pages 1238-1247

  Pan, Jianji ^a,b   Tang, Tianlan ^a   Xu, Luying ^a   Lu, Jiade J ^b   Lin, Senan ^a   Qiu, Sufang ^a   Chen, Gang ^a   Tham, Ivan W K ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cyclooxygenase 2; epidermal growth factor receptor; nasopharyngeal neoplasms; prognosis; vascular endothelial growth factor

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT DURATION;

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883050102     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23116     Document Type: Article

References (44)

1. Wei WI, Sham JS,. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-2054.
2. Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys 2001; 50: 1181-1189.
3. Heng DM, Wee J, Fong KW, et al. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 1999; 86: 1912-1920.
4. Cooper JS, Cohen R, Stevens RE,. A comparison of staging systems for nasopharyngeal carcinoma. Cancer 1998; 83: 213-219.
5. Thomas GR, Nadiminti H, Regalado J,. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005; 86: 347-363.
6. Chou J, Lin YC, Kim J, et al. Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck 2008; 30: 946-963.
7. Pan J, Kong L, Lin S, Chen G, Chen Q, Lu JJ,. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. Laryngoscope 2008; 118: 1970-1975.
8. Xu L, Pan J, Wu J, et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break. Radiother Oncol 2010; 96: 94-99.
9. Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005; 61: 1107-1116.
10. Hui AB, Lo KW, Teo PM, To KF, Huang DP,. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol 2002; 20: 467-473.
11. Leong JL, Loh KS, Putti TC, Goh BC, Tan LK,. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004; 114: 153-157.
12. Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 2003; 25: 864-872.
13. Milas L, Fan Z, Andratschke NH, Ang KK,. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004; 58: 966-971.
14. Chua DT, Nicholls JM, Sham JS, Au GK,. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 11-20.
15. Taheri-Kadkhoda Z, Magnusson B, Svensson M, Mercke C, Björk-Eriksson T,. Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck 2009; 31: 482-492.
16. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005; 23: 3568-3576.
17. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
18. Lu T, Zhao C, Chen C, Gao L, Lang J, Pan J, Hu C, Jin F, Wang R, Xie, C,. An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): preliminary report. J Clin Oncol 2010; 28:(suppl; abstr 5577).
19. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-13311.
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
21. Ferrara N,. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
22. Teknos TN, Cox C, Yoo S, et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 2002; 24: 1004-1011.
23. Tanigaki Y, Nagashima Y, Kitamura Y, Matsuda H, Mikami Y, Tsukuda M,. The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int J Mol Med 2004; 14: 389-395.
24. Krishna SM, James S, Balaram P,. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res 2006; 115: 85-90.
25. Li YH, Hu CF, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 2008; 6: 1.
26. Xueguan L, Xiaoshen W, Yongsheng Z, Chaosu H, Chunying S, Yan F,. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol (R Coll Radiol) 2008; 20: 606-612.
27. Kyzas PA, Cunha IW, Ioannidis JP,. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005; 11: 1434-1440.
28. Kim TJ, Lee YS, Kang JH, Kim YS, Kang CS,. Prognostic significance of expression of VEGF and Cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR. J Surg Oncol 2011; 103: 46-52.
29. Schimming R, Reusch P, Kuschnierz J, Schmelzeisen R,. Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance? J Craniomaxillofac Surg 2004; 32: 176-181.
30. Artese L, Rubini C, Ferrero G, Fioroni M, Santinelli A, Piattelli A,. Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma. Anticancer Res 2001; 21: 689-695.
31. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
32. Chen WC, McBride WH, Chen SM, et al. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies. Head Neck 2005; 27: 503-512.
33. Kim K, Wu HG, Park SW, Kim CJ, Park CI,. Expression of cyclooxygenase (COX)-2 as a prognostic factor in nasopharyngeal cancer. Cancer Res Treat 2004; 36: 187-191.
34. Loong SL, Hwang JS, Li HH, et al. Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). Radiat Oncol 2009; 4: 23.
35. Chen J, Ran Y, Hong C, Chen Z, You Y,. Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein. Cytotechnology 2010; 62: 431-438.
36. Soo RA, Wu J, Aggarwal A, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 2006; 17: 1625-1630.
37. Xue WP, Bai SM, Luo M, Bi ZF, Liu YM, Wu SK,. Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma. Oral Oncol 2011; 47: 753-757.
38. Tao Q, Chan AT,. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007; 9: 1-24.
39. Fennewald S, van Santen V, Kieff E,. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 1984; 51: 411-419.
40. Li HP, Chang YS,. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 2003; 10: 490-504.
41. Zheng H, Li LL, Hu DS, Deng XY, Cao Y,. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol 2007; 4: 185-196.
42. Miller WE, Earp HS, Raab-Traub N,. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995; 69: 4390-4398.
43. Sheen TS, Huang YT, Chang YL, et al. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J Cancer Res 1999; 90: 1285-1292.
44. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A 2001; 98: 6905-6910.